Rochester, NY 7/11/2009 2:26:00 AM
Stock Market Update - CYTR - CytRx Files Report with the FDA in Response to the Partial Clinical Hold on its Phase 2b Arimoclomol ALS Trial
CytRx Corporation CYTR
Stock Market Update - CYTR - CytRx Files Report with the FDA in Response to the Partial Clinical Hold on its Phase 2b Arimoclomol ALS Trial
---
CytRx Corporation CYTR
Last Trade: 0.98
Day's Range: 0.97 - 1.05
52wk Range: 0.23 - 1.21
Volume: 397,383
COMPANY "In The News"
CytRx Corporation a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, has filed a report with the U.S. Food and Drug Administrations (FDA) in response to the Agency’s partial clinical hold on the Company’s Phase 2b efficacy clinical trial with its molecular chaperone regulator drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
COMPANY DETAILS
CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers.
---
At WhisperfromWallStreet.com we specialize in understand the markets, particularly the penny stock market and understand what makes penny stocks increase. In a word it is exposure and by that we mean making the investing public aware of a particular stock, via an investor awareness campaign. Our tracking is second to none with our alerts in 2009 producing an average price gain of 80%+. If you'd like to track our results or receive your own alerts based on our experience, sign up now at... WhisperfromWallStreet.com
---
It's important that every investor be aware of our disclaimer which can be read in its entirety :
http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT NOTE: This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
